Denali Therapeutics Inc.
DNLI
$24.20
-$0.72-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -3.87% | 0.18% | 5.63% | 2.01% | 3.24% |
| Gross Profit | 4.73% | -0.18% | -5.63% | -2.01% | -3.57% |
| SG&A Expenses | 24.10% | 28.45% | 29.52% | 26.98% | 16.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.24% | 6.19% | 10.65% | 6.89% | 5.79% |
| Operating Income | -1.57% | -6.19% | -10.65% | -6.89% | -6.06% |
| Income Before Tax | -6.76% | -11.91% | -21.23% | -16.66% | -14.14% |
| Income Tax Expenses | 50.00% | 50.00% | 50.00% | 126.67% | 126.67% |
| Earnings from Continuing Operations | -6.77% | -11.91% | -21.23% | -16.67% | -14.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.77% | -11.91% | -21.23% | -16.67% | -14.15% |
| EBIT | -1.57% | -6.19% | -10.65% | -6.89% | -6.06% |
| EBITDA | -0.87% | -5.26% | -9.67% | -6.00% | -5.45% |
| EPS Basic | -1.07% | -7.88% | -15.30% | -5.30% | 1.62% |
| Normalized Basic EPS | 0.60% | -6.13% | -7.99% | 3.51% | 9.49% |
| EPS Diluted | -1.07% | -7.88% | -15.30% | -5.30% | 1.62% |
| Normalized Diluted EPS | 0.60% | -6.13% | -7.99% | 3.51% | 9.49% |
| Average Basic Shares Outstanding | 5.81% | 3.88% | 4.98% | 9.46% | 14.83% |
| Average Diluted Shares Outstanding | 5.81% | 3.88% | 4.98% | 9.46% | 14.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |